Lincoln, NE 5/18/2011 (PennyPayDay) -- Genta Incorporated (OTC:GNTA) yesterday announced, in a press release, that data from clinical trials of the Company's late-stage compounds, Genasense(R) (oblimersen sodium) Injection and tesetaxel, will be presented at the 2011 annual meeting of the American Society of Clinical Oncology (ASCO). The meeting will be held from June 3-7 in Chicago, IL.Highlights of the presentations include final results, including overall survival and durable response rate, from AGENDA -- the Phase 3 trial of Genasense(R) in advanced melanoma. In addition, final survival results from a trial in advanced melanoma that combined Genasense(R) plus temozolomide and Abraxane(R) will be presented, including data from patients who received Genasense as a 1-hour, twice-weekly, intravenous infusion.
Reports on clinical trials using tesetaxel, the leading oral taxane in clinical development, will also be presented, including Phase 2 studies as 1st-line therapy for patients with hormone-refractory breast cancer and as 2nd-line therapy using a flat (non weight-based) dose in patients with advanced gastric cancer. Additional reports include results of a clinical study that showed no effect of food on tesetaxel pharmacokinetics, which has eliminated overnight fasting requirements prior to dosing.
Genta is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer.
For more information about Genta, please visit our website at: www.genta.com.
No comments:
Post a Comment